Citations 23

Mild cognitive impairment: a concept in evolution

Journal of Internal Medicine | March 8, 2014 | Volume: 275 | Issue: 3 | Pages: 214-228

10.1111/joim.12190 | PMID 24605806

Abstract The construct of mild cognitive impairment ( MCI ) has evolved over the past 10 years since the publication of the new MCI definition at the K ey S ymposium in 2003, but the core criteria have remained unchanged. The construct has been extensively used worldwide, both in clinical and in research settings, to define the grey area between intact cognitive functioning and clinical dementia. A rich set of data regarding occurrence, risk factors and progression of MCI has been generated. Discrepancies between studies can be mostly explained by differences in the operationalization of the criteria, differences in the setting where the criteria have been applied, selection of subjects and length of follow‐up in longitudinal studies. Major controversial issues that remain to be further explored are algorithmic versus clinical classification, reliability of clinical judgment, temporal changes in cognitive performances and predictivity of putative biomarkers. Some suggestions to further develop the MCI construct include the tailoring of the clinical criteria to specific populations and to specific contexts. The addition of biomarkers to the clinical phenotypes is promising but requires deeper investigation. Translation of findings from the specialty clinic to the population setting, although challenging, will enhance uniformity of outcomes. More longitudinal population‐based studies on cognitive ageing and MCI need to be performed to clarify all these issues.
Activity enhances dopaminergic long-duration response in Parkinson disease

Neurology | March 30, 2012 | Volume: 78 | Issue: 15 | Pages: 1146-1149

10.1212/wnl.0b013e31824f8056 | PMID 22459675

Creating a transatlantic research enterprise for preventing Alzheimer's disease

Alzheimer's & Dementia | June 26, 2009 | Volume: 5 | Issue: 4 | Pages: 361-366

10.1016/j.jalz.2009.05.158 | PMID 19560106

In recognition of the global problem posed by Alzheimer's disease and other dementias, an international think‐tank meeting was convened by Biocat, the Pasqual Maragall Foundation, and the Lou Ruvo Brain Institute in February 2009. The meeting initiated the planning of a European Union‐North American collaborative research enterprise to expedite the delay and ultimate prevention of dementing disorders. The key aim is to build parallel and complementary research infrastructure that will support international standardization and inter‐operability among researchers in both continents. The meeting identified major challenges, opportunities for research resources and support, integration with ongoing efforts, and identification of key domains to influence the design and administration of the enterprise.